NEW YORK (GenomeWeb News) – Oligonucleotide synthesis startup Oligo Factor has opened a production facility in Holliston, Mass., the privately funded company said last week.
The company was founded in 2006 and specializes in "medium-scale" synthesis of DNA and RNA — on the order of tens of milligrams to multiple grams of oligos.
According to the company, the benefits of oligo synthesis on this scale are “predictably high quality, excellent yields, and low cost of manufacturing.”

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.